Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: An expert consensus document of the Association for Percutaneous Cardiovascular Interventions and the Polish Cardiac Society;Stanowisko grupy ekspertów dotycza̧ce zastosowania stentów oraz balonów uwalniaja̧cych leki antyproliferacyjne u pacjentów z choroba̧ wieńcowa̧ przyjȩte przez Asocjacjȩ Interwencji Sercowo-Naczyniowych i Polskie Towarzystwo Kardiologiczne

Postepy w Kardiologii Interwencyjnej

Volumn 7, Issue 1, 2011, Pages 20-55

  Witkowski, Adam ^a   Opolski, Maksymilian P ^a   Dudek, Dariusz ^b   Lesiak, MacIej ^c   Legutko, Jacek ^b   Wojakowski, Wojciech ^d   Ochała, Andrzej ^d   MacIejewski, Paweł ^e   Deptuch, Tomasz ^a   Araszkiewicz, Aleksander ^c   Ciećwierz, Dariusz ^f   Gil, Robert ^g   Grajek, Stefan ^c   Poloński, Lech ^d  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e GROCHOWSKI HOSPITAL   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g Centralny Szpital Kliniczny   (Poland)

Author keywords

Drug eluting balloons; Drug eluting stents; Randomized clinical trials

Indexed keywords

ARTICLE; BARE METAL STENT; CARDIOVASCULAR RISK; CONSENSUS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING BALLOON; DRUG ELUTING STENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; NON INVASIVE PROCEDURE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAFETY; STABLE CORONARY ARTERY DISEASE; STENT THROMBOSIS;

EID: 79953868813     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2011.21188     Document Type: Article

References (203)

1. Stettler C, Wandel S, Allemann S i wsp. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007; 370: 937-948. (Pubitemid 47393576)
2. Spaulding C, Daemen J, Boersma E i wsp. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989-997. (Pubitemid 46376799)
3. Stone GW, Moses JW, Ellis SG i wsp. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008. (Pubitemid 46376800)
4. Kastrati A, Mehilli J, Pache J i wsp. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039. (Pubitemid 46376803)
5. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010; 56: S1-42.
6. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27: 2784-2814. (Pubitemid 44871464)
7. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440-1455. (Pubitemid 46648381)
8. Lagerqvist B, James SK, Stenestrand U i wsp. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019. (Pubitemid 46376801)
9. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010; 56: S43-78.
10. Silber S, Borggrefe M, Böhm M i wsp. Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK. Clin Res Cardiol 2008; 97: 548-563.
11. Silber S, Albertsson P, Aviles FF i wsp. Guidelines for Percutaneous Coronary Interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr i wsp. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: 216-235. (Pubitemid 43005194)
13. Mauri L, Orav EJ, Candia SC i wsp. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005; 112: 2833-2839. (Pubitemid 41641678)
14. Biondi-Zoccai G, Agostini P, Sheiban I. Last nail in the coffin of late lumen loss? EuroInterv 2008; 4: 29-32.
15. Park SJ, Shim WH, Ho DS i wsp. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-1545. (Pubitemid 36437930)
16. Park DW, Hong MK, Mintz GS i wsp. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol 2006; 48: 2432-2439. (Pubitemid 44881217)
17. Wang TY, Hasselblad V, Peterson JL i wsp. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of secondgeneration drug-eluting stents. Am Heart J 2007; 153: 743-748. (Pubitemid 46602145)
18. Krucoff MW, Kereiakes DJ, Petersen JL i wsp. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008; 51: 1543-1552. (Pubitemid 351512313)
19. Silber S. RESOLUTE - Klinisches Studienprogramm: Der nächste logische Schritt. Symposium: DES Rückschläge und Fortschritte: 74. Jahrestagung der DGK, Mannheim, 2008.
20. Kaiser C, Brunner-La Rocca HP, Buser PT i wsp. Incremental costeffectiveness of drug-eluting stents compared with a thirdgeneration bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005; 366: 921-992.
21. Kaiser C, Galatius S, Erne P i wsp. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363: 2310-2319.
22. Schampaert E, Cohen EA, Schlüter M i wsp. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115. (Pubitemid 38352997)
23. Pache J, Dibra A, Mehilli J i wsp. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005; 26: 1262-1268. (Pubitemid 41435455)
24. Mancone M, Sardella G, Conti G i wsp. A prospective, randomized trial of selective versus routine paclitaxel-eluting stent use in patients with multivessel disease: cost-effectiveness analysis at 12 through 24 months (the CHREDIT trial). TCT, Washington, DC, late breaking trials, 2007.
25. Lansky AJ, Costa RA, Mintz GS i wsp. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109: 1948-1954. (Pubitemid 38544484)
26. Maresta A, Varani E, Balducelli M i wsp. Comparison of effectiveness and safety of sirolimus-eluting stents versus baremetal stents in patients with diabetes mellitus (from the italian multicenter randomized DESSERT Study). Am J Cardiol 2008; 101: 1560-1566.
27. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ i wsp. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112: 2175-2183. (Pubitemid 41475813)
28. Fajadet J, Wijns W, Laarman GJ i wsp. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806. (Pubitemid 44268230)
29. Schofer J, Schlüter M, Gershlick AH i wsp. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099. (Pubitemid 37222332)
30. Morice MC, Bestehorn HP, Carrié D i wsp. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carboncoated carbostents. The randomized JUPITER II trial. EuroIntervention 2006; 2: 45-52.
31. Lemos PA. Percutaneous Intervention with biodegradable-polymer based paclitaxel-eluting, sirolimuseluting, or bare stents for the treatment of de novo coronary lesions (PAINT). EuroPCR, Barcelona, late breaking trials, 2008.
32. Suttorp MJ, Laarman GJ, Rahel BM i wsp. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 2006; 114: 921-928. (Pubitemid 44337135)
33. Morice MC, Serruys PW, Sousa JE i wsp. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. N Engl J Med 2002; 346: 1773-1780.
34. Erglis A, Narbute I, Kumsars I i wsp. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50: 491-497. (Pubitemid 47126783)
35. Kelbaek H, Thuesen L, Helqvist S i wsp. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006; 47: 449-455. (Pubitemid 43063270)
36. Grube E, Lansky A, Hauptmann KE i wsp. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004; 44: 1368-1372. (Pubitemid 39303936)
37. Baumgart D, Klauss V, Baer F. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007; 50: 1627-1634. (Pubitemid 47562680)
38. Ardissino D, Cavallini C, Bramucci E i wsp. Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292: 2727-2734. (Pubitemid 39628251)
39. Moses JW, Leon MB, Popma JJ i wsp. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
40. Serruys PW, Ong AT, Piek JJ i wsp. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroInterv 2005; 1: 157-164.
41. Grube E, Hauptmann K, Buellesfeld L i wsp. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. EuroInterv 2005; 1: 53-57.
42. Grube E, Silber S, Hauptmann KE i wsp. TAXUS I: six- and twelvemonth results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42. (Pubitemid 36070930)
43. Colombo A, Drzewiecki J, Banning A i wsp. Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794. (Pubitemid 37022118)
44. Stone GW, Ellis SG, Cox DA i wsp. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
45. Stone GW, Ellis SG, Cannon L i wsp. Comparison of a polymerbased paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-1223. (Pubitemid 41352109)
46. Dawkins KD, Grube E, Guagliumi G i wsp. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112: 3306-3313. (Pubitemid 43739376)
47. Kirtane AJ, Stone G. Comprehensive meta-analysis of DES vs. BMS randomized trials and registries. ACC, Chicago, late breaking trials, 2008.
48. Dibra A, Kastrati A, Mehilli J i wsp. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670. (Pubitemid 41175674)
49. Mehilli J, Dibra A, Kastrati A i wsp. Randomized trial of paclitaxeland sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-266. (Pubitemid 43100018)
50. Kim YH, Park SW, Lee SW i wsp. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006; 114: 2148-2153.
51. Morice MC, Colombo A, Meier B i wsp. Sirolimus- vs. paclitaxeleluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904.
52. Windecker S, Remondino A, Eberli FR i wsp. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662. (Pubitemid 41175673)
53. Galløe AM, Thuesen L, Kelbaek H i wsp. SORT OUT II: a prospective, multi-center, large-scale randomized trial of Paclitaxel- and Sirolimus-eluting stents in "real-world" lesions: nine-month clinical results. TCT, late breaking trials, 2006.
54. Han YL, Wang XZ, Jing QM i wsp. Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2006; 34: 123-126.
55. Petronio AS, De Carlo M, Branchitta G i wsp. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 2007; 49: 539-546. (Pubitemid 46177439)
56. Chieffo A, Romagnoli E, Ferrari A i wsp. Randomized comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel (Taxus vs. Costar) eluting stents in coronary lesions: a single center experience (the ABSOLUTE trial). TCT, Washington, DC, late breaking trials, 2007.
57. Kandzari DE, Leon MB, Popma JJ i wsp. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447. (Pubitemid 44881222)
58. Leon M. ENDEAVOR IV: a randomized comparison of a Zotarolimus-eluting stent and a Paclitaxel-eluting stent in patients with coronary artery disease. TCT, Washington, DC, late breaking trials, 2007.
59. Byrne RA, Mehilli J, Iijima R i wsp. A polymer-free dual drugeluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009; 30: 923-931.
60. Rasmussen K, Maeng M, Kaltoft A i wsp. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010; 375: 1090-1099.
61. Park DW, Kim YH, Yun SC i wsp. Comparison of zotarolimuseluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) randomized trial. J Am Coll Cardiol 2010; 56: 1187-1195.
62. Serruys PW, Ruygrok P, Neuzner J i wsp. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
63. Stone GW, Midei M, Newman W i wsp. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-1913. (Pubitemid 351574920)
64. Stone GW, Rizvi A, Newman W i wsp. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
65. Grube E. SPIRIT V Diabetic RCT 9-month angiographic and 1-year clinical follow-up. EuroPCR, Paris, Late Breaking Registries and Trial Updates, 2010.
66. Kedhi E, Joesoef KS, McFadden E i wsp. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-209.
67. Kim HS. EXCELLENT: A Prospective Randomized Trial of Everolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
68. Jensen LO. SORT OUT 4: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
69. Chieffo A, Romagnoli E, Ferrari A. Randomized comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs Paclitaxel (Taxus vs Costar) eluting stents in coronary lesions: a single center experience (the ABSOLUTE trial). TCT, Washington, DC, late breaking trials, 2007.
70. Lee CW. A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel. TCT, San Francisco, late breaking trials, 2009.
71. Grube E. BIOFREEDOM: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
72. Verheye S. A randomized, multicenter study of the Pimecrolimuseluting and Paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries (the GENESIS trial). ACC, Chicago, late breaking trials, 2008.
73. Adriaenssens T, Mehilli J, Wessely R i wsp. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007; 49: 1265-1271. (Pubitemid 46476843)
74. Mehilli J, Kastrati A, Wessely R i wsp. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymerbased paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
75. Mehilli J, Byrne RA, Wieczorek A i wsp. Randomized trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29: 1975-1982.
76. Byrne RA, Kastrati A, Kufner S i wsp. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-2449.
77. Mehilli J. ISAR-TEST-5: A Prospective Randomized Trial of Polymer-Free Sirolimus-/Probucol-Eluting Stents Compared to Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
78. Windecker S, Serruys PW, Wandel S i wsp. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
79. Spaulding C. Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial. Euro PCR, Barcelona, late breaking trials, 2009.
80. Chevalier B, Serruys PW, Silber S i wsp. Randomised comparison of Nobori®, Biolimus A9™-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007; 2: 426-434.
81. Chevalier B, Silber S, Park SJ i wsp. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2. Circ Cardiovasc Interv 2009; 2: 188-195.
82. Takeshita S. A randomised comparison of Nobori biolimus A9 eluting-stent with Cypher sirolimus eluting stent for coronary revascularisation in Japanese population. EuroPCR, Paris, Late Breaking Registries and Trial Updates, 2010.
83. Serruys PW, Silber S, Garg S i wsp. Comparison of zotarolimuseluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-146.
84. Klomp M. TRIAS HR: DES Outperform Genous Stent in High-Risk Patients. TCT, Washington, DC, Late Breaking Trials, 2010.
85. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv 2008; 1: 524-532.
86. Gray W, Yeung A. A randomized, controlled trial to evaluate the safety and efficacy of the ZoMaxxTM drug-eluting coronary stent system compared to the Taxus Express2TM Paclitaxel-eluting coronary stent system in de novo coronary artery lesions (the ZOMAXX II trial). EuroPCR, Barcelona, Late Breaking Registries and Trial Updates, 2008.
87. Windecker S. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. ESC, Stockholm, Late Breaking Registries and Trial Updates, 2010.
88. Schiele F, König A, Rieber J i wsp. Intravascular ultrasound assessment of sirolimus-eluting stent implantation versus betairradiation for the treatment of in-stent restenosis. Results of the randomized BRADES trial. ESC, Vienna, Late Breaking Registries and Trial Updates, 2007.
89. Kastrati A, Mehilli J, von Beckerath N i wsp. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171. (Pubitemid 40095867)
90. Alfonso F, Pérez-Vizcayno MJ, Hernandez R i wsp. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006; 47: 2152-2160. (Pubitemid 43795079)
91. Holmes DR Jr, Teirstein P, Satler L i wsp. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within baremetal stents: the SISR randomized trial. JAMA 2006; 295: 1264-1273.
92. Stone GW, Ellis SG, O'Shaughnessy CD i wsp. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006; 295: 1253-1263.
93. Ellis SG, O'Shaughnessy CD, Martin SL i wsp. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart 2008; 29: 1625-1634. (Pubitemid 351958446)
94. Scheller B, Hehrlein C, Bocksch W i wsp. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355: 2113-2124. (Pubitemid 44749319)
95. Scheller B, Hehrlein C, Bocksch W i wsp. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated catheter. Clin Res Cardiol 2008; 97: 773-781.
96. Unverdorben M, Vallbracht C, Cremers B i wsp. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-2994.
97. Hamm CW. Paclitaxel-eluting PTCA-balloon in combination with the Coroflex Blue stent vs. the sirolimus coated Cypher stent in the treatment of advanced coronary artery disease. AHA, Orlando, Scientific Sessions, 2009.
98. Mehilli J, Byrne RA, Tiroch K i wsp. Randomized trial of paclitaxelversus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55: 2710-2716.
99. Chevalier B. CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents. TCT, Washington, DC, Late Breaking Trials, 2010.
100. Kelbaek H, Thuesen L, Helqvist S i wsp. Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008; 118: 1155-1162.
101. Tierala I, Syvänne M, Kupari M. Comparison of paclitaxel-eluting with bare metal stents in aute myocardial infarction - the HAAMU-STENT-study. TCT, Washington, DC, Late Breaking Trials, 2006.
102. Stone GW, Lansky AJ, Pocock SJ i wsp. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
103. van der Hoeven BL, Liem SS, Jukema JW i wsp. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51: 618-626. (Pubitemid 351186867)
104. Valgimigli M, Campo G, Percoco G i wsp. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799. (Pubitemid 351549970)
105. Di Lorenzo E, De Luca G, Sauro R i wsp. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009; 2: 515-523.
106. Dirksen MT, Vink MA, Suttorp MJ i wsp. Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. EuroIntervention 2008; 4: 64-70.
107. Lee JH, Kim HS, Lee SW i wsp. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: PROSIT trial. Catheter Cardiovasc Interv 2008; 72: 25-32.
108. Menichelli M, Parma A, Pucci E i wsp. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930. (Pubitemid 46694284)
109. Díaz de la Llera LS, Ballesteros S, Nevado J i wsp. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007; 154: 164.e1-6.
110. Valgimigli M, Percoco G, Malagutti P i wsp. Tirofiban and sirolimuseluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293: 2109-2117. (Pubitemid 40617063)
111. Karjalainen PP, Ylitalo A, Niemelä M i wsp. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention 2008; 4: 234-241.
112. Spaulding C, Henry P, Teiger E i wsp. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006; 355: 1093-104. (Pubitemid 44394916)
113. Lee CW, Park DW, Lee SH i wsp. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 1370-1376.
114. Ferenc M, Gick M, Kienzle RP i wsp. Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions. Eur Heart J 2008; 29: 2859-2867.
115. Colombo A, Bramucci E, Saccá S i wsp. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009; 119: 71-78.
116. Chen SL, Santoso T, Zhang JJ i wsp. A Randomized Clinical Study Comparing Double Kissing Crush With Provisional Stenting for Treatment of Coronary Bifurcation Lesions Results From the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) Trial. J Am Coll Cardiol 2011; 57: 914-920.
117. Steigen TK, Maeng M, Wiseth R i wsp. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006; 114: 1955-1961. (Pubitemid 44665390)
118. Erglis A, Kumsars I, Niemelä M i wsp. Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Interv 2009; 2: 27-34.
119. Colombo A, Moses JW, Morice MC i wsp. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109: 1244-1249. (Pubitemid 38372783)
120. de la Cruz KI, Tsai PI, Cohn WE, Cooley DA. Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting. Curr Atheroscler Rep 2008; 10: 434-437.
121. Boudriot E. Randomized multicenter trial between PCI with sirolimus-eluting stent versus CABG for unprotected left main stenosis. EuroPCR, Barcelona, late breaking trials, 2009.
122. Mehilli J, Kastrati A, Byrne RA i wsp. Paclitaxel- versus sirolimuseluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009; 53: 1760-1768.
123. Buszman PE, Kiesz SR, Bochenek A i wsp. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 2008; 51: 538-545. (Pubitemid 351146684)
124. Serruys PW, Morice MC, Kappetein AP i wsp. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
125. Morice MC, Serruys PW, Kappetein AP i wsp. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010; 121: 2645-2653.
126. Serruys PW. SYNTAX at 3 Years: PCI Matches CABG in Left Main Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
127. Wijns W, Kolh P, Danchin N i wsp. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555.
128. Park DW, Seung KB, Kim YH i wsp. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol 2010; 56: 117-124.
129. Rubartelli P, Petronio AS, Guiducci V i wsp. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 2010; 31: 2014-2020.
130. Werner GS, Krack A, Schwarz G i wsp. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxeleluting stents. J Am Coll Cardiol 2004; 44: 2301-2306. (Pubitemid 39647602)
131. Kelbaek H, Helqvist S, Thuesen L i wsp. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. Am Heart J 2006; 152: 882-886. (Pubitemid 44740156)
132. Rahel BM, Laarman GJ, Kelder JC i wsp. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J 2009; 157: 149-155.
133. van den Branden BJL. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with Sirolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroPCR, Paris, late breaking trials, 2010.
134. Lotan C, Almagor Y, Kuiper K i wsp. Sirolimus-eluting stent in chronic total occlusion: the SICTO study. J Interv Cardiol 2006; 19: 307-312. (Pubitemid 44185821)
135. Nakamura S, Muthusamy TS, Bae JH i wsp. Impact of sirolimuseluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol 2005; 95: 161-166. (Pubitemid 40092078)
136. Ge L, Iakovou I, Cosgrave J i wsp. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005; 26: 1056-1062. (Pubitemid 40839905)
137. Vermeersch P, Agostoni P, Verheye S i wsp. Randomized doubleblind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48: 2423-2431. (Pubitemid 44895571)
138. Vermeersch P, Agostoni P, Verheye S i wsp. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50: 261-267. (Pubitemid 47039289)
139. Brilakis ES, Lichtenwalter C, de Lemos JA i wsp. A randomized controlled trial of a paclitaxel-eluting stent versus a similar baremetal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53: 919-928.
140. Chu WW, Rha SW, Kuchulakanti PK i wsp. Efficacy of sirolimuseluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-37. (Pubitemid 41828119)
141. Ellis SG, Kandzari D, Kereiakes DJ i wsp. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007; 19: 404-409. (Pubitemid 47509462)
142. Wöhrle J, Nusser T, Kestler HA i wsp. Comparison of the slowrelease polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007; 96: 70-76. (Pubitemid 46233208)
143. Bansal D, Muppidi R, Singla S i wsp. Percutaneous intervention on the saphenous vein bypass grafts-long-term outcomes. Catheter Cardiovasc Interv 2008; 71: 58-61. (Pubitemid 351158347)
144. Hlatky MA, Boothroyd DB, Bravata DM i wsp. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: 1190-1197.
145. Hueb W, Lopes NH, Gersh BJ i wsp. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082-1089. (Pubitemid 46673170)
146. Radke PW, Friese K, Buhr A i wsp. Comparison of coronary restenosis rates in matched patients with versus without diabetes mellitus. Am J Cardiol 2006; 98: 1218-1222. (Pubitemid 44584109)
147. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-1749.
148. Kastrati A, Schömig A, Elezi S i wsp. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428-1436. (Pubitemid 27486458)
149. Abizaid A, Kornowski R, Mintz GS i wsp. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589. (Pubitemid 28435240)
150. Chan C, Zambahari R, Kaul U i wsp. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv 2008; 72: 591-600.
151. Lee SW, Park SW, Kim YH i wsp. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52: 727-733.
152. Maresta A, Varani E, Balducelli M i wsp. Comparison of effectiveness and safety of sirolimus-eluting stents versus baremetal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008; 101: 1560-1566.
153. Maeng M, Jensen LO, Galloe AM i wsp. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009; 103: 345-349.
154. Jensen LO. DiabeDES III Trial: hyperplasia and angiographic late lumen loss after sirolimus eluting and zotarolimus eluting stent implantation in diabetic patients. ESC, Barcelona, Late Breaking Registries and Trial Updates, 2009.
155. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ i wsp. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007; 28: 1946-1952. (Pubitemid 47579538)
156. Kirtane AJ, Patel R, O'Shaughnessy C i wsp. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009; 2: 967-976.
157. Silber S, Herdeg C. Drug-eluting Stents bei Patienten mit Diabetes mellitus: Eine kritische Analyse der aktuellen Datenlage aus randomisierten Studien. Herz 2008; 33: 196-205. (Pubitemid 351581157)
158. Garg P, Normand SL, Silbaugh TS i wsp. Drug-eluting or baremetal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008; 118: 2277-2285.
159. Stettler C, Allemann S, Wandel S i wsp. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337: a1331.
160. Frobert O, Lagerqvist B, Carlsson J i wsp. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53: 1660-1667.
161. Kapur A, Hall RJ, Malik IS i wsp. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55: 432-440.
162. Kirtane AJ, Gupta A, Iyengar S i wsp. Safety and efficacy of drugeluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
163. Nayak AK, Kawamura A, Nesto RW i wsp. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 2006; 70: 1026-1029. (Pubitemid 44161740)
164. Chen MS, John JM, Chew DP i wsp. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264. (Pubitemid 43866610)
165. Stone GW, Ellis SG, Colombo A i wsp. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007; 115: 2842-2847. (Pubitemid 46869671)
166. Mauri L. ENDEAVOR pooled safety analysis in 1217 patients to 3 years. ACC, Chicago, late breaking trials, 2008.
167. Ong AT, Hoye A, Aoki J i wsp. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947-953. (Pubitemid 40342824)
168. Mauri L, Hsieh WH, Massaro JM i wsp. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029. (Pubitemid 46376802)
169. Cutlip DE, Windecker S, Mehran R i wsp. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351. (Pubitemid 46685903)
170. van Werkum JW, Heestermans AA, Zomer AC i wsp. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-1409.
171. Pfisterer M, Brunner-La Rocca HP i wsp. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591. (Pubitemid 44881238)
172. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45: 941-946. (Pubitemid 40342823)
173. Wenaweser P, Morger C, Cook S i wsp. Late and very late stent thrombosis in patients with drug-eluting stents. J Am Coll Cardiol 2007; 47: 4B.
174. Girod JP, Mulukutla SR, Marroquin OC. Off-label use of stents: bare-metal versus drug-eluting stents. Expert Rev Cardiovasc Ther 2008; 6: 1095-1106.
175. Serruys P. SPIRIT II - A clinical evaluation of the XIENCETM V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Clinical, Angiographic and IVUS 2 year results. ACC, Chicago, late breaking trials, 2008.
176. Stone G. SPIRIT III - A prospective, randomized trial comparing an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: 2-year clinical follow-up. EuroPCR, Barcelona, late breaking trials, 2008.
177. Smits PC. COMPARE: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease. TCT, Washington, DC, Late Breaking Trials, 2010.
178. Dibra A. Meta-analysis of randomized trials assessing the outcome of patients treated with everolimus-eluting stents versus paclitaxel-eluting stents. ESC, Stockholm, Late Breaking Registries and Trial Updates, 2010.
179. Daemen J, Wenaweser P, Tsuchida K i wsp. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxeleluting stents in routine clinical practice: data from a large twoinstitutional cohort study. Lancet 2007; 369: 667-678. (Pubitemid 46281313)
180. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008; 156: 141-147.
181. Beohar N, Davidson CJ, Kip KE i wsp. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297: 1992-2000. (Pubitemid 46740351)
182. Marroquin OC, Selzer F, Mulukutla SR i wsp. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008; 358: 342-352. (Pubitemid 351159233)
183. Kappetein AP. The two-year outcomes of the SYNTAX trial. ESC, Barcelona, Late Breaking Registries and Trial Updates, 2009.
184. Poldermans D, Bax JJ, Boersma E i wsp. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30: 2769-2812.
185. Camm AJ, Kirchhof P, Lip GY i wsp. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
186. Spertus JA, Kettelkamp R, Vance C i wsp. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803-2809. (Pubitemid 44305292)
187. Airoldi F, Colombo A, Morici N i wsp. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754. (Pubitemid 47255992)
188. Schulz S, Schuster T, Mehilli J i wsp. Stent thrombosis after drugeluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4 year period. Eur Heart J 2009; 30: 2714-2721.
189. Serruys PW, Daemen J. Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115: 1433-1439. (Pubitemid 46648379)
190. Park DW, Yun SC, Lee SW i wsp. Stent thrombosis, clinical events, and in?uence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents. J Am Coll Cardiol Intv 2008; 1: 494-503.
191. Tanzilli G, Greco C, Pelliccia F i wsp. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [twoyear ClOpidOgrel need] study). Am J Cardiol 2009; 104: 1357-1361.
192. Feres F. Update from ongoing DAPT studies: Brazil OPTIMIZE randomised trial. TCT, San Francisco, late breaking trials, 2009.
193. Byrne RA, Schulz S, Mehilli J i wsp. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EF?cacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009; 157: 620-4.e2.
194. Mauri L. Updates from ongoing DAPT studies: United States: DAPT randomized trial. TCT, San Francisco, late breaking trials, 2009.
195. Van de Werf F. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur Heart J 2009; 30: 1695-1702.
196. Wiviott SD, Braunwald E, McCabe CH i wsp. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
197. Wallentin L, Becker RC, Budaj A i wsp. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
198. Schomig A. Ticagrelor - is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009; 361: 1108-1111.
199. Cook S, Ladich E, Nakazawa G i wsp. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
200. Nordmann AJ, Bucher H, Hengstler P i wsp. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev 2005; CD005313.
201. Kastrati A, Dibra A, Spaulding C i wsp. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-2713. (Pubitemid 350139205)
202. Pocock SJ, Lansky AJ, Mehran R i wsp. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008; 51: 23-32.
203. Daemen J, Simoons ML, Wijns W i wsp. ESC Forum on Drug Eluting Stents. Eur Heart J 2009; 30: 152-161.